查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1829590

糖尿病护理设备市场（按设备类型、技术、交付方式、胰岛素类型、分销管道和最终用户划分）—2025-2032 年全球预测

Diabetes Care Devices Market by Device Type, Technology, Delivery Mode, Insulin Type, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年糖尿病护理设备市场将成长至 125.8 亿美元，复合年增长率为 19.11%。

主要市场统计数据
基准年2024年 31亿美元
预计2025年 36.8亿美元
预测年份：2032年 125.8亿美元
复合年增长率（%） 19.11%

糖尿病护理设备领域正处于关键时刻，这得益于技术的快速成熟、医疗服务模式的转变以及患者和付款人期望的不断提升。感测器精度、演算法控制和无线互通性的进步，重新定义了临床医生和糖尿病患者对设备的期望：持续的洞察、可操作的自动化以及与日常生活和临床工作流程的无缝整合。同时，医疗保健系统正在优先考虑治疗结果和价值，推动报销途径和采购决策，优先考虑那些能够显着改善血糖控制、减少併发症并降低总护理成本的设备。

随着这些力量的汇聚，製造商、技术合作伙伴和医疗保健提供者正在完善其产品蓝图和商业策略。创新日益以患者为中心，注重易用性、减轻设备负担和数据透明度。监管机构正在不断改进其指导方针，以适应软体主导的疗法和组合药物，而供应链和製造考量如今在商业性可行性中发挥着至关重要的作用。总而言之，这些动态为一个加速颠覆的时代奠定了基础，在这个时代，临床有效性、连结性、监管敏捷性和营运弹性将决定市场主导。

闭合迴路自动化、即时连接、智慧交付选项和分散护理模式如何重塑糖尿病设备的开发和商业化

糖尿病照护设备领域正在经历一场变革，重新定义治疗模式和商业性模式。首先，结合持续感知和自动化胰岛素输送的闭合迴路系统已从利基研究原型转变为具有商业性可行性的治疗方案。因此，临床路径正在不断调整，以纳入演算法决策支援和远端监控，护理也从偶发性诊疗转变为持续性护理关係。

同时，连网型设备和云端平台的普及创造了更丰富的纵向资料集，使更个人化的治疗调整和人群层面的分析成为可能。此类数据的可用性促进了设备製造商、软体开发商和付款方之间的伙伴关係，从而催生了一个互通性和安全数据交换为商业性差异化因素的生态系统。同时，智慧笔和先进注射辅助器具的兴起也拓展了胰岛素给药的选择，提供了弥合生活方式便利性和临床有效性之间差距的选择。远端医疗、家庭诊断和远距滴定正在减少对集中式诊所的依赖，并由此重塑分销策略、教育推广和客户支援模式。

评估 2025 年美国关税及其对糖尿病医疗设备筹资策略、定价能力和製造足迹的连锁影响

美国将在2025年之前征收关税，这已产生一系列累积效应，波及糖尿病护理设备采购、定价策略和供应链。依赖跨境采购的製造商正面临不断上升的投入成本，不得不立即重新评估筹资策略和供应商合约。一些公司正在透过加速近岸外包或多元化供应商来降低风险，而有些公司则正在寻求合约条款来分担或吸收关税相关成本。这些营运调整会影响生产前置作业时间和库存管理，同时平衡成本控制和服务水准承诺。

从商业性角度来看，关税给器械定价和报销谈判带来了压力。付款人和采购团体对单价和生命週期支出的关注度日益提高，从而影响了医院和诊所的处方决策和竞标结果。一些製造商选择暂时消化关税影响以维持市场进入，而另一些製造商则实施了与特定产品线挂钩的价格调整。同时，关税环境反映出企业为降低贸易风险而采取的长期倡议，鼓励对国内製造能力的投资以及与本地委託製造製造商建立策略联盟。最终，关税事件加速了采购、製造地决策和贸易条款的结构性转变，这将对当前金融週期之外的竞争动态产生影响。

深度細項分析揭示了产品类型、感测和输送技术、胰岛素配方、通路和最终用户偏好如何相互影响，从而形成产品策略

细緻的细分视角揭示了不同设备系列、技术、给药方式、胰岛素製剂、管道和最终用户之间独特的成长方向和差异化的临床价值。按设备类型划分，市场构成涵盖从采用全闭合迴路和混合闭合迴路架构的全自动人工胰腺系统，到涵盖持续血糖监测、瞬时血糖监测和自我监测的血糖监测设备。注射辅助器具包括输液器、笔式针头和注射器针头，而胰岛素笔则包括预填充一次性笔、可重复使用笔和日益复杂的智慧笔。胰岛素帮浦进一步分为贴片帮浦和管泵，两者在穿戴性和储液容量方面各有优劣。

从技术面来看，连续血糖监测本身可分为即时和回顾性连续血糖监测，它们不同于闪光血糖监测和自我监测方法。输送模式可分为连续和间歇输送，以适应不同的临床特征和患者偏好。胰岛素类型从中效到超长效，常用的长效型如地特胰岛素和甘精胰岛素，以及速效型态如Aspart、赖谷胰岛素和Lispro胰岛素，其塑造设备相容性及给药演算法。分销管道包括直销、医院药房、线上通路和零售药局，零售药局进一步分为连锁药局和独立药局。最后，最终用户细分涵盖诊断中心、居家医疗保健机构和医院/诊所，后者包括专门的糖尿病诊所和全科医生。

综合起来，这些细分市场决定了产品设计重点、临床定位和上市策略。例如，智慧笔和连续技术与居家医疗部署和线上销售紧密相关，而混合和全闭合迴路系统在早期采用期间则需要医院、糖尿病诊所和专业诊断服务的全面支援。因此，製造商必须将其技术选择与通路和最终用户管道结合，以优化临床效果和商业性应用。

对影响美洲、欧洲、中东和非洲以及亚太地区商业性成功的法规结构、报销驱动因素和采用途径进行区域比较

区域动态显着影响美洲、欧洲、中东和非洲以及亚太地区的监管和报销框架及应用节奏。在美洲，对付款人模式和基于价值的合约的高度重视正促使製造商展示其成果和成本抵消。这有利于那些能够显着减少急性事件和医院利用率的设备，并正在加速互联繫统在已建立覆盖途径的人群中的应用。相反，欧洲、中东和非洲呈现出多种多样的管理体制和采购惯例。一些欧洲市场的集中核准和国内价格谈判与其他司法管辖区的异质准入形成鲜明对比，因此需要差异化的市场进入和证据产生策略。

亚太市场呈现多样化的需求驱动因素。高人口密度和不断上升的渗透率创造了规模化发展的机会，而报销和收入水准的差异则要求提供分级产品和进行通路创新。在某些市场，本地製造伙伴关係和许可安排已成为规避进口关税和获得优先供应商地位的关键。一些国家正在迅速采用持续监测和闭合迴路方法，而其他国家则优先考虑经济高效的间歇给药解决方案和强大的供应链韧性。因此，製造商必须根据区域付款人的期望和监管现状，定制其临床证据基础、定价方法和伙伴关係模式，以最大限度地提高产品采用率和报销成功率。

领先的糖尿病设备製造商的策略和竞争行动专注于平台整合、伙伴关係、证据生成和供应弹性

糖尿病设备领域的主要企业正在将产品创新与生态系统伙伴关係和资本约束相结合。关键的策略行动包括：扩展其平台，提供整合感测、交付和分析的端到端解决方案；与胰岛素製造商和数位医疗公司建立垂直伙伴关係；以及选择性地投资于製造能力，以更好地管理供应连续性。一些公司强调软体即服务模式，将分析和护理管理功能与设备硬体一起收益；而另一些公司则透过更小的尺寸、更佳的可穿戴性和更好的用户体验来进一步提升其硬体的差异化。

竞争动态也受到併购、授权合约和共同开发契约的影响，这些协议可以加快复杂组合产品的上市时间。成功的公司往往将临床证据生成纳入其商业化计划的早期阶段，并将随机和真实世界证据与付款人的决策需求相结合。此外，他们还会投资于客户教育、专家培训和上市后监测，以增强临床可信度并减少器械损耗。最后，认识到采购团队越来越多地将环境影响纳入采购决策，越来越多的公司正在考虑製造和包装的永续性，并将声誉和成本纳入考虑。

设备製造商需要采取切实可行的策略措施，协调临床价值、供应弹性、互通性和区域商业化方法，以实现持续成长

行业领导者应采取一系列切实可行的行动，确保在技术加速发展和付款人审查日益严格的市场环境中保持持久优势。首先，优先考虑端到端的临床价值，将产品设计与对付款人和提供者至关重要的可衡量结果相结合，并将证据生成嵌入产品生命週期，以加快报销时间。其次，透过结合近岸製造选项和多层级供应商协议，实现供应链多元化，以减轻关税和零件中断的影响。第三，透过投资互通性和开放标准，确保产品能够整合到电子健康记录和人口健康管理平台中，从而提高医疗系统的采用率。

第四，开发分级商业产品，以满足不同地区不同的可负担性需求，将高端、完全整合的系统与针对资源匮乏市场的简化、经济高效的替代方案相结合。第五，与胰岛素製造商、数位疗法公司和远端保健提供者建立策略伙伴关係，打造捆绑式解决方案，协调相关人员的奖励机制。第六，加速支持临床医师培训和病患入职的上市后项目，减少实施阻力，提高病患留存率。这些努力将有助于製造商应对复杂的法规，满足不断变化的临床预期，并在日益以结果为导向的市场中占据长期份额。

透过严格的混合方法研究检验见解和建议，该研究将监管、临床和商业性证据与专家访谈和情境分析相结合

本报告采用混合方法整合证据，将全面的二手资料研究与一手质性研究结合，以确保研究的稳健性。二手资料包括监管备案文件、同行评审临床文献、公司技术揭露和政策声明，以建立事实和监管背景。一手资料研究包括与临床意见领袖、采购专家和高级商务主管进行的结构化访谈，以及与付款人和糖尿病护理协调员进行有针对性的讨论，以检验商业和报销动态。

分析过程包括：将定性检验与已发表的临床结果和监管指南进行交叉验证；情境分析以对关税和供应中断的影响进行压力测试；以及对访谈结果进行主题编码，以突出反復出现的应用障碍和促成因素。品质保证步骤包括由主题专家进行独立审查，并协调差异以得出平衡的结论。研究行为始终遵循伦理道德和资料隐私通讯协定，专有商业资讯得到保密处理，并且尽可能将综合结果反映为共识，而非单一来源的断言。

综合策略要务强调向综合、主导糖尿病护理解决方案的过渡以及扩大规模所需的营运弹性

总而言之，糖尿病护理设备产业正从渐进式改进转向由自动化、互联互通和不断变化的护理模式所驱动的系统级转型。那些摆脱以产品为中心、拥抱能够提供可衡量临床和经济价值的整合解决方案的相关人员，将最有可能抓住新的机会。同时，透过多元化供应链、区域製造伙伴关係和积极的关税减免所展现的营运韧性，正成为竞争的必需品，而非仅仅是后勤部门事务。

未来的成功取决于能否将医疗设备产生的大量数据转化为切实可行的临床工作流程，能否透过强有力的证据包确保支付方的一致性，能否提供根据当地情况量身定制的灵活商业模式。对于製造商、投资者和医疗保健系统而言，我们的使命非常明确：追求创新，使糖尿病护理更简单、更安全、更便捷，同时建立商业性和营运实力，以扩大规模并交付这些创新。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 透过整合持续血糖监测和人工智慧预测分析平台实现主动血糖控制
  • 利用光谱技术和微针阵列开发非侵入式血糖监测感测器
  • 封闭回路型胰岛素输送系统的出现，将自动输送演算法与个人数据回馈结合
  • 透过蓝牙连接扩展远端医疗胰岛素笔，实现远端剂量追踪和药物依从性监测
  • 投资多参数穿戴式生物感测器，同时监测血糖值、心率和活动指标
  • FDA核准双激素人工胰臟原型，透过封闭回路型系统输送胰岛素和升糖素
  • 采用标准化互通性通讯协定，将 CGM 数据整合到各种糖尿病管理应用程式和电子健康记录中
  • 以患者为中心的设备设计不断发展，重点关注穿戴舒适度以及针对老年人和儿科用户的简化介面

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第 8 章糖尿病护理设备市场（按设备类型）

  • 人工胰臟系统
    • 完全封闭回路型
    • 混合闭合迴路
  • 血糖监测装置
    • 持续血糖监测
    • Flash血糖监测
    • 血糖自我监测
  • 注射辅助器
    • 点滴器
    • 笔针
    • 针头
  • 胰岛素笔
    • 一次性注射笔（预填充）
    • 可重复使用的笔
    • 智慧笔
  • 胰岛素帮浦
    • 贴片帮浦
    • 管泵
  • 胰岛素注射器

第九章糖尿病治疗设备市场：按技术

  • 持续血糖监测
    • 即时连续血糖监测
    • 回顾性持续血糖监测
  • Flash血糖监测
  • 血糖自我监测
    • 血糖值监测仪
    • 《采血针》
    • 测试纸

第 10 章糖尿病治疗设备市场（依给药方式）

  • 持续给药
  • 间歇给药

第 11 章糖尿病治疗设备市场（按胰岛素类型）

  • 中效型
  • 长效
    • 地特米尔
    • 甘精胰岛素
  • 快速起效
    • Aspart
    • Glulisine
    • Lispro
  • 短效
  • 超长效

第 12 章糖尿病护理设备市场（依通路）

  • 直销
  • 医院药房
  • 线上管道
  • 零售药局
    • 连锁药局
    • 独立药房

第十三章糖尿病护理设备市场（依最终用户）

  • 诊断中心
  • 居家医疗
  • 医院和诊所
    • 糖尿病诊所
    • 综合诊所

第 14 章糖尿病治疗设备市场：按地区

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章糖尿病护理设备市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章糖尿病照护设备市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • Medtronic plc
    • Roche Holding AG
    • Dexcom, Inc.
    • Becton, Dickinson and Company
    • Insulet Corporation
    • Tandem Diabetes Care, Inc.
    • Terumo Corporation
    • Kyowa Kirin Co., Ltd.
    • Ypsomed Holding AG
Product Code: MRR-43539E5D2EA5

The Diabetes Care Devices Market is projected to grow by USD 12.58 billion at a CAGR of 19.11% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.10 billion
Estimated Year [2025] USD 3.68 billion
Forecast Year [2032] USD 12.58 billion
CAGR (%) 19.11%

The diabetes care devices landscape is at a pivotal moment, driven by rapid technological maturation, shifting care delivery models, and intensifying expectations from patients and payers alike. Advances in sensor accuracy, algorithmic control, and wireless interoperability have recalibrated what clinicians and people living with diabetes expect from devices: continuous insights, actionable automation, and seamless integration into daily life and clinical workflows. At the same time, healthcare systems are emphasizing outcomes and value, prompting reimbursement pathways and procurement decisions to prioritize devices that demonstrably improve glycemic control, reduce complications, and lower total cost of care.

As these forces converge, manufacturers, technology partners, and healthcare providers are refining product roadmaps and commercial strategies. Innovation is increasingly patient-centric, focusing on ease of use, reduced device burden, and data transparency. Regulatory authorities are evolving guidance to accommodate software driven therapeutics and combination products, while supply chain and manufacturing considerations now play an outsized role in commercial viability. Taken together, these dynamics set the stage for a period of accelerated disruption where clinical efficacy, connectivity, regulatory agility, and operational resilience will determine market leadership.

How closed-loop automation, real-time connectivity, smart delivery options, and decentralized care models are reshaping diabetes device development and commercialization

The landscape of diabetes care devices has undergone transformative shifts that are redefining therapeutic paradigms and commercial playbooks. First, closed-loop systems that combine continuous sensing with automated insulin delivery have transitioned from niche research prototypes to commercially viable therapeutic options. As a result, clinical pathways are adapting to incorporate algorithmic decision support and remote monitoring, moving care from episodic encounters to continuous care relationships.

Concurrently, the proliferation of connected devices and cloud platforms has created richer longitudinal datasets that enable more personalized therapy adjustments and population-level analytics. This data availability is catalyzing partnerships between device manufacturers, software developers, and payers, fostering an ecosystem where interoperability and secure data exchange are commercial differentiators. In parallel, the rise of smart pens and advanced injection aids has broadened the options for insulin delivery, offering alternatives that can bridge the gap between lifestyle convenience and clinical efficacy. Finally, the industry is witnessing a shift toward decentralization of care: telehealth, home diagnostics, and remote titration are reducing the reliance on centralized clinics, and in doing so, reshaping distribution strategies, educational outreach, and customer support models.

Assessment of the 2025 United States tariff measures and their cascading effects on sourcing strategies, pricing dynamics, and manufacturing footprints across diabetes devices

The imposition of tariffs in the United States during 2025 has introduced a set of cumulative effects that ripple across procurement, pricing strategies, and supply chains for diabetes care devices. Manufacturers that rely on cross-border component sourcing have encountered escalated input costs, prompting immediate reassessment of sourcing strategies and supplier contracts. In response, some organizations accelerated nearshoring initiatives or diversified supplier bases to mitigate exposure, while others sought contractual clauses to share or absorb tariff related costs. These operational adjustments have implications for production lead times and inventory management as firms balance cost containment with service level commitments.

From a commercial perspective, tariffs have created pressure on device pricing and reimbursement negotiations. Payers and purchasing groups have become more vigilant about unit costs and lifecycle expenditures, which in turn influences formulary decisions and tender outcomes for hospitals and clinics. Some manufacturers opted to absorb tariff impacts temporarily to preserve market access, while others introduced price adjustments tied to specific product lines. At the same time, the tariff environment has incentivized investment in domestic manufacturing capabilities and strategic partnerships with local contract manufacturers, reflecting a longer-term pivot to reduce trade risk. Ultimately, the tariff episode accelerated structural shifts in sourcing, manufacturing footprint decisions, and commercial terms that will influence competitive dynamics beyond the immediate fiscal cycle.

Deep segmentation analysis revealing how device type, sensing and delivery technologies, insulin formulations, channels, and end user settings intersect to shape product strategies

A nuanced view of segmentation reveals divergent growth vectors and differentiated clinical value across device families, technologies, delivery modes, insulin formulations, channels, and end users. When examined by device type, the market composition ranges from fully automated artificial pancreas systems comprising full closed loop and hybrid closed loop architectures to glucose monitoring devices that cover continuous glucose monitoring, flash glucose monitoring, and self-monitoring blood glucose. The injection aids spectrum includes infusion sets, pen needles, and syringe needles, while insulin pens span prefilled disposable pens, reusable pens, and increasingly sophisticated smart pens. Insulin pumps are further categorized into patch pumps and tubed pumps, each offering distinct tradeoffs in wearability and reservoir capacity.

Looking through a technology lens, continuous glucose monitoring itself bifurcates into real-time continuous glucose monitoring and retrospective continuous glucose monitoring, and remains distinct from flash glucose monitoring and self-monitoring blood glucose approaches; the latter includes glucose meters, lancets, and test strips. Delivery mode segmentation divides offerings into continuous delivery and intermittent delivery, which align to different clinical profiles and patient preferences. Insulin types span intermediate acting through ultra long acting formulations, with commonly used long acting analogues such as detemir and glargine and rapid acting analogues including aspart, glulisine, and lispro shaping device compatibility and dosing algorithms. Distribution channel dynamics encompass direct sales, hospital pharmacies, online channels, and retail pharmacies, with retail channels further split between chain and independent pharmacies. Finally, end user segmentation covers diagnostic centers, home care settings, and hospitals and clinics, where the latter includes specialized diabetes clinics as well as general clinics.

Taken together, these segmentation layers intersect to inform product design priorities, clinical positioning, and go-to-market approaches. For example, smart pens and continuous technologies align strongly with home care adoption and online distribution, while hybrid and full closed loop systems require integrated support from hospitals, diabetes clinics, and specialized diagnostic services during early adoption phases. Manufacturers should therefore map technology choices to distribution and end user pathways to optimize clinical impact and commercial uptake.

Comparative regional intelligence on regulatory frameworks, reimbursement drivers, and adoption pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine commercial success

Regional dynamics materially influence regulatory pathways, reimbursement frameworks, and adoption tempos across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, payer models and a strong emphasis on value-based contracting have pushed manufacturers to demonstrate outcomes and cost offsets. This has favored devices that enable measurable reductions in acute events and hospital utilization, and has accelerated uptake of connected systems in populations with established coverage pathways. Conversely, Europe, Middle East & Africa presents a mosaic of regulatory regimes and procurement practices; centralized approvals and national pricing negotiations in some European markets contrast with heterogeneous access in other jurisdictions, requiring differentiated market entry and evidence generation strategies.

Asia-Pacific markets exhibit diverse demand drivers, where high population density and rising prevalence create scale opportunities, while variable reimbursement and income levels necessitate tiered product offerings and channel innovation. In several markets, local manufacturing partnerships and licensing arrangements have been critical to navigating import duties and securing preferred provider status. Across regions, technology adoption curves differ: while some countries rapidly embrace continuous monitoring and closed-loop approaches, others prioritize cost-effective intermittent delivery solutions and robust supply chain resilience. Manufacturers should therefore calibrate clinical evidence dossiers, pricing approaches, and partnership models in accordance with regional payer expectations and regulatory realities to maximize adoption and reimbursement success.

Strategic behaviors and competitive moves among leading diabetes device manufacturers focused on platform integration, partnerships, evidence generation, and supply resilience

Leading companies in the diabetes devices space are aligning product innovation with ecosystem partnerships and capital discipline. Key strategic behaviors include platform expansion to deliver end-to-end solutions that combine sensing, delivery, and analytics; vertical partnerships with insulin manufacturers and digital health firms; and selective investments in manufacturing capabilities to enhance control over supply continuity. Some organizations emphasize software as a service models, monetizing analytics and care management features alongside device hardware, while others double down on hardware differentiation through miniaturization, improved wearability, and enhanced user experience.

Competitive dynamics are also shaped by M&A, licensing, and co-development agreements that accelerate time to market for complex combination products. Companies that succeed tend to integrate clinical evidence generation into commercialization plans early, aligning randomized and real-world evidence to payer decision needs. Additionally, leaders invest in customer education, professional training, and post-market surveillance to reinforce clinical trust and reduce device attrition. Finally, a growing number of firms are committing to sustainability in manufacturing and packaging as a reputational and cost consideration, recognizing that procurement teams increasingly factor environmental impact into purchasing decisions.

Actionable strategic imperatives for device manufacturers to align clinical value, supply resilience, interoperability, and regional commercialization approaches for sustained growth

Industry leaders should pursue a set of pragmatic actions to secure durable advantage in a landscape defined by technological acceleration and payer scrutiny. First, prioritize end-to-end clinical value by aligning product design with measurable outcomes that matter to payers and providers, and embed evidence generation in product lifecycles to shorten reimbursement timelines. Second, diversify supply chains by combining nearshore manufacturing options with multi-tier supplier agreements to mitigate tariff exposure and component disruptions. Third, invest in interoperability and open standards to ensure devices can integrate into electronic health records and population health platforms, thereby increasing adoption by health systems.

Fourth, develop tiered commercial offerings that address distinct regional affordability profiles, pairing premium, fully integrated systems with simplified, cost-effective alternatives for resource constrained markets. Fifth, cultivate strategic partnerships with insulin producers, digital therapeutics firms, and telehealth providers to create bundled solutions that align incentives across stakeholders. Sixth, accelerate post-market programs that support clinician training and patient onboarding, reducing friction in adoption and improving retention. Together, these actions will enable manufacturers to navigate regulatory complexities, respond to evolving clinical expectations, and capture long-term share in an increasingly outcomes-oriented market.

Rigorous mixed methods research combining regulatory, clinical, and commercial evidence with expert interviews and scenario analysis to validate insights and recommendations

This report synthesizes evidence using a mixed-methods approach that combines comprehensive secondary research with primary qualitative inquiry and triangulation to ensure robustness. Secondary inputs include regulatory filings, peer-reviewed clinical literature, company technical disclosures, and policy announcements that establish the factual backdrop and regulatory context. Primary research incorporated structured interviews with clinical opinion leaders, procurement specialists, and senior commercial executives, along with targeted discussions with payers and diabetes care coordinators to validate commercial and reimbursement dynamics.

Analytical processes included cross-validation of qualitative insights against published clinical outcomes and regulatory guidance, scenario analysis to stress test the implications of tariffs and supply disruptions, and thematic coding of interview outputs to surface recurring adoption barriers and enablers. Quality assurance steps encompassed independent review by subject matter experts and reconciliation of divergent viewpoints to create balanced conclusions. Ethical research conduct and data privacy protocols were maintained throughout, ensuring that proprietary commercial information was handled under confidentiality and that synthesized findings reflect consensus where possible rather than single-source assertions.

Synthesis of strategic imperatives underscoring the transition to integrated, evidence-driven diabetes care solutions and the operational resilience required for scale

In conclusion, the diabetes care devices sector is transitioning from incremental improvement to systems-level transformation, driven by automation, connectivity, and shifting care paradigms. Stakeholders who move beyond product centric thinking to embrace integrated solutions that deliver measurable clinical and economic value will be best positioned to capture emerging opportunities. At the same time, operational resilience-manifested through diversified supply chains, regional manufacturing partnerships, and proactive tariff mitigation-has become a competitive necessity rather than a back-office concern.

Looking ahead, success will hinge on the ability to translate rich device-generated data into actionable clinical workflows, to secure payer alignment through strong evidence packages, and to offer flexible commercial models adapted to regional contexts. For manufacturers, investors, and healthcare systems alike, the mandate is clear: pursue innovations that make diabetes care simpler, safer, and more accessible, while building the commercial and operational muscle to deliver those innovations at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of continuous glucose monitoring with AI-powered predictive analytics platforms for proactive glycemic control
  • 5.2. Development of non-invasive glucose monitoring sensors utilizing spectroscopic technologies and microneedle arrays
  • 5.3. Emergence of closed-loop insulin delivery systems combining automated dosing algorithms and personalized data feedback
  • 5.4. Expansion of telehealth-enabled insulin pens with Bluetooth connectivity for remote dose tracking and adherence monitoring
  • 5.5. Investment in multi-parameter wearable biosensors for simultaneous monitoring of glucose, heart rate and activity metrics
  • 5.6. FDA clearance trends for bi-hormonal artificial pancreas prototypes delivering both insulin and glucagon through closed-loop systems
  • 5.7. Adoption of standardized interoperability protocols to integrate CGM data across diverse diabetes management apps and electronic health records
  • 5.8. Growth of patient-centric device designs focusing on wearable comfort and simplified interfaces for elderly and pediatric users

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Care Devices Market, by Device Type

  • 8.1. Artificial Pancreas Systems
    • 8.1.1. Full Closed Loop
    • 8.1.2. Hybrid Closed Loop
  • 8.2. Glucose Monitoring Devices
    • 8.2.1. Continuous Glucose Monitoring
    • 8.2.2. Flash Glucose Monitoring
    • 8.2.3. Self Monitoring Blood Glucose
  • 8.3. Injection Aids
    • 8.3.1. Infusion Sets
    • 8.3.2. Pen Needles
    • 8.3.3. Syringe Needles
  • 8.4. Insulin Pens
    • 8.4.1. Prefilled Disposable Pens
    • 8.4.2. Reusable Pens
    • 8.4.3. Smart Pens
  • 8.5. Insulin Pumps
    • 8.5.1. Patch Pumps
    • 8.5.2. Tubed Pumps
  • 8.6. Insulin Syringes

9. Diabetes Care Devices Market, by Technology

  • 9.1. Continuous Glucose Monitoring
    • 9.1.1. Real Time Continuous Glucose Monitoring
    • 9.1.2. Retrospective Continuous Glucose Monitoring
  • 9.2. Flash Glucose Monitoring
  • 9.3. Self Monitoring Blood Glucose
    • 9.3.1. Glucose Meters
    • 9.3.2. Lancets
    • 9.3.3. Test Strips

10. Diabetes Care Devices Market, by Delivery Mode

  • 10.1. Continuous Delivery
  • 10.2. Intermittent Delivery

11. Diabetes Care Devices Market, by Insulin Type

  • 11.1. Intermediate Acting
  • 11.2. Long Acting
    • 11.2.1. Detemir
    • 11.2.2. Glargine
  • 11.3. Rapid Acting
    • 11.3.1. Aspart
    • 11.3.2. Glulisine
    • 11.3.3. Lispro
  • 11.4. Short Acting
  • 11.5. Ultra Long Acting

12. Diabetes Care Devices Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacies
  • 12.3. Online Channels
  • 12.4. Retail Pharmacies
    • 12.4.1. Chain Pharmacies
    • 12.4.2. Independent Pharmacies

13. Diabetes Care Devices Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Home Care
  • 13.3. Hospitals And Clinics
    • 13.3.1. Diabetes Clinics
    • 13.3.2. General Clinics

14. Diabetes Care Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Diabetes Care Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Diabetes Care Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. Medtronic plc
    • 17.3.3. Roche Holding AG
    • 17.3.4. Dexcom, Inc.
    • 17.3.5. Becton, Dickinson and Company
    • 17.3.6. Insulet Corporation
    • 17.3.7. Tandem Diabetes Care, Inc.
    • 17.3.8. Terumo Corporation
    • 17.3.9. Kyowa Kirin Co., Ltd.
    • 17.3.10. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. DIABETES CARE DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. DIABETES CARE DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIABETES CARE DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COU